Actavis, Inc. (ACT) and Valeant Pharmaceuticals International, Inc. (VRX, VRX.TO) Wednesday said that Actavis has reached settlement agreements with Medicis Pharmaceutical Corp., a subsidiary of Valeant, resolving outstanding patent litigation related to Actavis' Abbreviated New Drug Application or ANDA for Clindamycin and Tretinoin Gel, a generic version of Ziana, as well as Actavis' ANDA for Imiquimod Cream, a generic version of Zyclara.
Ziana is a lincosamide antibiotic and retinoid combination product indicated for the topical treatment of acne vulgaris in patients 12 years or older.
Zyclara is a prescription medicine for skin use only to treat actinic keratosis on the full face or balding scalp in adults with a normal immune function.
Under the terms of the agreement related to Actavis' generic version of Ziana, Actavis may launch its generic product in July 2016, or earlier under certain circumstances.
Under the terms of the agreement related to the generic version of Zyclara, Actavis may launch its generic product on January 1, 2019, or earlier under some circumstances.
Valeant will receive a share of the economics from the generic products sold under the agreements. Other terms of the agreements were not disclosed.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.